iWisdom and Europe Pharma Network BCN Form Strategic Joint Venture to Scale Biotech Assets in Under Served Markets

3 min read 463 words

iWisdom and Europe Pharma Partners Network BCN (EPN) today announced the formation of a strategic Joint Venture (JV) to accelerate the commercialization of late-stage and early-commercialized biotech assets across the Balkans, Eastern Europe, and MENA.

The JV brings together two organizations with complementary strengths, united by a shared focus on execution and accountable value creation. It combines EPN’s regionally embedded operating platform across the Balkans, and Eastern Europe with iWisdom’s late-stage commercialization expertise and MENA execution footprint, creating an execution-led gateway for assets entering complex and underserved markets.

Over the past three years, Europe Pharma Partners Network BCN has deliberately focused on building and solidifying its regional execution platform, actively delivering multiple Named Patient Programs and managing a portfolio that already generates more than $1 billion in topline revenue. This work has established deep regulatory fluency, local market leadership, and durable operating infrastructure across its core regions.

In parallel, iWisdom has spent the last several years working with biotech companies, asset owners, and investors to support late-stage assets from Phase III through launch and post-launch value optimization, drawing on global Big Pharma execution heritage. With a strong base in London and strategic hubs in Boston and Riyadh, iWisdom has built a growing commercialization footprint across MENA, aligning assets with capital, partners, and regional growth opportunities.

Through the Joint Venture, the partners aim to expand the existing EPN portfolio revenue base by approximately 25% over the next three years, driven by disciplined execution across specialist and rare disease assets, vaccines, and selected dermatology assets.

The upcoming JPM Week will represent a key milestone for the Joint Venture, marking its first formal engagement with biotech companies, asset owners, and investors.

Berk Gundogan Baruch, Partner at Europe Pharma Partners Network and former Pfizer executive, said:

“We have spent the past three years building a strong execution platform across the Balkans, Eastern Europe, and Russia. Partnering with iWisdom allows us to extend this foundation into late-stage biotech assets with scale and discipline.”

Ishil K. Ozturk, Founder and Managing Partner of iWisdom | Ex-GSK Executive | MD, GSK Client, added:

“This Joint Venture brings together proven execution platforms and late-stage commercialization expertise to expand an already established revenue base across regions where hands-on delivery is critical to success.”

---

About Europe Pharma Network BCN 

Europe Pharma Partners Network BCN is a regional execution platform founded by former Pfizer and GSK leaders, with active operations across the Balkans and Eastern Europe. The network has executed multiple Named Patient Programs and manages a portfolio focused on biosimilars and rare diseases.

About iWisdom

iWisdom is an execution-led biopharma commercialization and strategic advisory group supporting late-stage and commercial assets across global and high-growth markets, with a strong base in London, strategic hubs in Boston and Riyadh, and an active MENA commercialization footprint.